Zacks
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
📈
AI Sentiment
Highly Positive
8/10
- Home
- MRK
as of 02-10-2026 3:57pm EST
$117.15
$0.50
-0.42%
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | RAHWAY |
| Market Cap: | 268.7B | IPO Year: | N/A |
| Target Price: | $121.00 | AVG Volume (30 days): | 14.0M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.28 | EPS Growth: | 8.01 |
| 52 Week Low/High: | $73.31 - $122.66 | Next Earning Date: | 02-03-2026 |
| Revenue: | $65,011,000,000 | Revenue Growth: | 1.31% |
| Revenue Growth (this year): | 5.02% | Revenue Growth (next year): | 5.31% |
| P/E Ratio: | 16.16 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered MRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.46%
73.46%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
Zachary Jennifer
Sell
EVP, General Counsel
MRK Feb 9, 2026
Avg Cost/Share
$119.15
Shares
121,573
Total Value
$14,485,690.41
Owned After
68,915.671
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 9, 2026
Avg Cost/Share
$118.41
Shares
10,000
Total Value
$1,184,101.00
Owned After
70,615.127
SEC Form 4
Williams David Michael
Sell
EVP,Chief Info&Digital Officer
MRK Feb 6, 2026
Avg Cost/Share
$121.91
Shares
5,000
Total Value
$609,525.00
Owned After
30,837.743
SEC Form 4
Oosthuizen Johannes Jacobus
Sell
President, U.S. Market
MRK Feb 6, 2026
Avg Cost/Share
$121.87
Shares
15,000
Total Value
$1,827,991.50
Owned After
21,197.389
SEC Form 4
DeLuca Richard R.
Sell
EVP&Pres, Merck Animal Heallth
MRK Feb 6, 2026
Avg Cost/Share
$120.92
Shares
37,685
Total Value
$4,557,024.71
Owned After
160,173.834
SEC Form 4
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 5, 2026
Avg Cost/Share
$121.88
Shares
20,000
Total Value
$2,437,676.00
Owned After
70,615.127
SEC Form 4
Litchfield Caroline
Sell
EVP & CFO
MRK Feb 4, 2026
Avg Cost/Share
$119.61
Shares
41,997
Total Value
$5,023,311.57
Owned After
90,192.194
SEC Form 4
Smart Dalton
Sell
SVP Fin. - Global Controller
MRK Feb 4, 2026
Avg Cost/Share
$119.68
Shares
6,400
Total Value
$765,920.00
Owned After
8,204.816
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 10, 2026 | Sell | $117.52 | 10,235 | $1,202,843.81 | 92,035.05 | |
| Zachary Jennifer | MRK | EVP, General Counsel | Feb 9, 2026 | Sell | $119.15 | 121,573 | $14,485,690.41 | 68,915.671 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 9, 2026 | Sell | $118.41 | 10,000 | $1,184,101.00 | 70,615.127 | |
| Williams David Michael | MRK | EVP,Chief Info&Digital Officer | Feb 6, 2026 | Sell | $121.91 | 5,000 | $609,525.00 | 30,837.743 | |
| Oosthuizen Johannes Jacobus | MRK | President, U.S. Market | Feb 6, 2026 | Sell | $121.87 | 15,000 | $1,827,991.50 | 21,197.389 | |
| DeLuca Richard R. | MRK | EVP&Pres, Merck Animal Heallth | Feb 6, 2026 | Sell | $120.92 | 37,685 | $4,557,024.71 | 160,173.834 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 5, 2026 | Sell | $121.88 | 20,000 | $2,437,676.00 | 70,615.127 | |
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 4, 2026 | Sell | $118.77 | 15,087 | $1,791,824.15 | 92,035.05 | |
| Litchfield Caroline | MRK | EVP & CFO | Feb 4, 2026 | Sell | $119.61 | 41,997 | $5,023,311.57 | 90,192.194 | |
| Smart Dalton | MRK | SVP Fin. - Global Controller | Feb 4, 2026 | Sell | $119.68 | 6,400 | $765,920.00 | 8,204.816 |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Simply Wall St.
Health Canada RSV Approval Adds New Angle To Merck Valuation Story
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
MT Newswires
Merck & Co. Insider Sold Shares Worth $765,920, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
The Wall Street Journal
The Dow Industrials Have Tilted More Toward Financials
📊
AI Sentiment
Positive
7/10
Compare MRK vs Leading Stocks
See how MRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.